265 related articles for article (PubMed ID: 18593921)
1. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.
Gough MJ; Ruby CE; Redmond WL; Dhungel B; Brown A; Weinberg AD
Cancer Res; 2008 Jul; 68(13):5206-15. PubMed ID: 18593921
[TBL] [Abstract][Full Text] [Related]
2. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
Kitamura N; Murata S; Ueki T; Mekata E; Reilly RT; Jaffee EM; Tani T
Int J Cancer; 2009 Aug; 125(3):630-8. PubMed ID: 19455675
[TBL] [Abstract][Full Text] [Related]
3. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells.
Burocchi A; Pittoni P; Gorzanelli A; Colombo MP; Piconese S
Eur J Immunol; 2011 Dec; 41(12):3615-26. PubMed ID: 22229156
[TBL] [Abstract][Full Text] [Related]
4. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
5. OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells.
Mousavi SF; Soroosh P; Takahashi T; Yoshikai Y; Shen H; Lefrançois L; Borst J; Sugamura K; Ishii N
J Immunol; 2008 Nov; 181(9):5990-6001. PubMed ID: 18941188
[TBL] [Abstract][Full Text] [Related]
6. Costimulation of CD8 T cell responses by OX40.
Bansal-Pakala P; Halteman BS; Cheng MH; Croft M
J Immunol; 2004 Apr; 172(8):4821-5. PubMed ID: 15067059
[TBL] [Abstract][Full Text] [Related]
7. Ox40 regulates the conversion and suppressive function of double-negative regulatory T cells.
Liu K; Ye H; Zhou J; Tian Y; Xu H; Sun X; Zhang D
Int Immunopharmacol; 2018 Dec; 65():16-22. PubMed ID: 30268799
[TBL] [Abstract][Full Text] [Related]
8. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
[TBL] [Abstract][Full Text] [Related]
9. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
Garrison K; Hahn T; Lee WC; Ling LE; Weinberg AD; Akporiaye ET
Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
[TBL] [Abstract][Full Text] [Related]
10. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.
Hendriks J; Xiao Y; Rossen JW; van der Sluijs KF; Sugamura K; Ishii N; Borst J
J Immunol; 2005 Aug; 175(3):1665-76. PubMed ID: 16034107
[TBL] [Abstract][Full Text] [Related]
11. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
[TBL] [Abstract][Full Text] [Related]
12. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
13. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
14. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.
Buchan S; Manzo T; Flutter B; Rogel A; Edwards N; Zhang L; Sivakumaran S; Ghorashian S; Carpenter B; Bennett C; Freeman GJ; Sykes M; Croft M; Al-Shamkhani A; Chakraverty R
J Immunol; 2015 Jan; 194(1):125-133. PubMed ID: 25404365
[TBL] [Abstract][Full Text] [Related]
15. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition.
Yu Q; Yue FY; Gu XX; Schwartz H; Kovacs CM; Ostrowski MA
J Immunol; 2006 Feb; 176(4):2486-95. PubMed ID: 16456009
[TBL] [Abstract][Full Text] [Related]
16. Circumventing tolerance at the T cell or the antigen-presenting cell surface: antibodies that ligate CD40 and OX40 have different effects.
Hochweller K; Sweenie CH; Anderton SM
Eur J Immunol; 2006 Feb; 36(2):389-96. PubMed ID: 16402409
[TBL] [Abstract][Full Text] [Related]
17. OX40 controls effector CD4+ T-cell expansion, not follicular T helper cell generation in acute Listeria infection.
Marriott CL; Mackley EC; Ferreira C; Veldhoen M; Yagita H; Withers DR
Eur J Immunol; 2014 Aug; 44(8):2437-47. PubMed ID: 24771127
[TBL] [Abstract][Full Text] [Related]
18. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.
Fujiwara S; Nagai H; Shimoura N; Oniki S; Yoshimoto T; Nishigori C
J Invest Dermatol; 2014 Jul; 134(7):1884-1892. PubMed ID: 24468748
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.
Andarini S; Kikuchi T; Nukiwa M; Pradono P; Suzuki T; Ohkouchi S; Inoue A; Maemondo M; Ishii N; Saijo Y; Sugamura K; Nukiwa T
Cancer Res; 2004 May; 64(9):3281-7. PubMed ID: 15126371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]